Tu canal independiente de oncología en español
Top resúmenes y presentaciones
ESMO 2024
GINECOLÓGICO
OVARIO
Datopotamab deruxtecan (Dato-DXd) in patients with
endometrial (EC) or ovarian cancer (OC): results from the
Phase 2 TROPION-PanTumor03 study
714MO
Mirvetuximab Soravtansine (MIRV) in Recurrent
Platinum-Sensitive Ovarian Cancer (PSOC) with High Folate
Receptor-Alpha (FRα) Expression: Results from the PICCOLO
Trial
718MO
Phase 3 MIRASOL Trial: Updated Overall Survival Results of
Mirvetuximab Soravtansine (MIRV) vs. Investigator’s Choice
Chemotherapy (ICC) in Patients (pts) with
Platinum-Resistant Ovarian Cancer (PROC) and High Folate
Receptor-Alpha (FRα) Expression
746P
Final overall survival (OS) from the Phase III
ATALANTE/ENGOT-ov29 trial evaluating atezolizumab (Atz)
versus placebo with standard chemotherapy (Cx) plus
bevacizumab (bev) in ovarian cancer (OC) patients (pts) with
platinum-sensitive relapse (PSR)
712MO
SOLACE2: A Phase 2 randomized trial of Olaparib (O) and
Durvalumab (D) with or without low dose
cyclophosphamide (LDCy) in platinum-sensitive recurrent
ovarian cancer (PSROC)
747P
Regístrate aquí para recibir más contenidos
Registrarse